yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Top Links You Must Click On

Lakewood-Amedex Inc. Appoints Marie E. Knight To Its Board Of Directors

SARASOTA, Fla., Dec. 4, 2012 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has elected Marie E. Knight to its board of directors.  Dr. Knight brings to the company her experience in both biotechnology equity research, including significant connections in the equity financing arena, and her years of high-level consulting on market intelligence in the pharmaceutical industry.  Dr. Knight will initially focus on helping the company to raise expansion capital and provide regulatory guidance as it prepares to move its Nu-2 topical anti-bacterial product to IND filing and into Phase I clinical trials in 2013. 

Dr. Knight has over 20 years in the healthcare industry, including 14 years in pharmaceutical and biotechnology equity research and as a consultant for numerous multinational pharmaceutical companies.  As a Senior Biotech Analyst at Avalon Research Group, a NASD research sell-side firm, she provided drug-pipeline analysis of publicly traded biotechnology companies and evaluation of venture capital opportunities.   She also has first-hand industry experience working at a small biotech company as a traveling developmental scientist.  In this capacity, she worked on-site for many pharmaceutical and biotech companies and collaborated with industry scientists at all stages of drug development, including basic research, pharmacokinetics, toxicology, QC, clinical testing, and manufacturing.  

She brings an international perspective as a consultant working for the last ten years with pharmaceutical teams across numerous therapeutic areas to provide actionable strategic direction.  In this role she has provided research and analysis for oncology, rheumatology, ophthalmology, infectious diseases and immunology projects, both for pre-approval and post-marketed products. 

Lakewood-Amedex's President and CEO, Steve Parkinson, commented "It is a pleasure to welcome a world-class executive of Marie Knight's standing to the board of directors.  Her hands-on intimate familiarity with the drug-development process will be invaluable in working with our team to successfully commercialize our products.  This experience brings to Lakewood-Amedex additional capabilities to navigate the regulatory environment and maximize assets to best align with future potential licensing and partnership opportunities."

Dr. Knight commented "Having researched many biotechnology companies in my time, I was greatly impressed with the breadth of the Lakewood-Amedex product portfolio and the quality of the company's science.  This sets them apart from most companies at this stage of development.  Also the management team has the right level of passion and chemistry that I can work with to help them make a great success of this very promising company.  I have already initiated communications with the FDA.  We expect to move the first product forward into the clinic rapidly and really put this company on the map."

About Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds, orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, cancer, influenza, and hepatitis, and a fully human monoclonal antibody for HUS.  The Company's products and technology are covered by an extensive patent portfolio consisting of 36 granted and/or issued patents and 29 pending patent applications filed on a worldwide basis covering all major pharmaceutical markets.  The Company's lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram-positive, gram-negative, and antibiotic-resistant bacteria and is expected to enter the clinic in 2013.

This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions.  Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements.  Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition.  Forward-looking statements speak only as to the date they are made.  The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.


Steve Parkinson

Marie E. Knight

President and CEO


Lakewood-Amedex Inc.

Lakewood-Amedex, Inc.

(941) 255 2515

(321) 223 3152

SOURCE Lakewood-Amedex Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
“The Internet of Things transforms the way organizations leverage machine data and gain insights from it,” noted Splunk’s CTO Snehal Antani, as Splunk announced accelerated momentum in Industrial Data and the IoT. The trend is driven by Splunk’s continued investment in its products and...
Interested in leveraging automation technologies and a cloud architecture to make developers more productive? Learn how PaaS can benefit your organization to help you streamline your application development, allow you to use existing infrastructure and improve operational efficiencies....
DevOps Summit at Cloud Expo 2014 Silicon Valley was a terrific event for us. The Qubell booth was crowded on all three days. We ran demos every 30 minutes with folks lining up to get a seat and usually standing around. It was great to meet and talk to over 500 people! My keynote was we...
Redis is not only the fastest database, but it has become the most popular among the new wave of applications running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 17th Cloud Expo, Dave Nielsen, Developer...
Application availability is not just the measure of “being up”. Many apps can claim that status. Technically they are running and responding to requests, but at a rate which users would certainly interpret as being down. That’s because excessive load times can (and will be) interpreted...
Cloud Foundry open Platform as a Service makes it easy to operate, scale and deploy application for your dedicated cloud environments. It enables developers and operators to be significantly more agile, writing great applications and deliver them in days instead of months. Cloud Foundr...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers